Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?
Author: Nikpour, M.
Stevens, W.
Proudman, S.
Buchbinder, R.
Prior, D.
Zochling, J.
Williams, T.
Gabbay, E.
Nandurkar, H.
Citation: Internal Medicine Journal, 2013; 43(5):599-603
Publisher: Blackwell Publishing Asia
Issue Date: 2013
ISSN: 1444-0903
Statement of
M. Nikpour, W. Stevens, S. M. Proudman, R. Buchbinder, D. Prior, J. Zochling, T. Williams, E. Gabbay and H. Nandurkar
Abstract: Pulmonary arterial hypertension (PAH) is a major cause of mortality in scleroderma and despite ‘advanced’ therapies confers a median survival of less than 5 years. Anticoagulation in systemic sclerosis-related PAH (SSc-PAH) is currently one of the most contentious issues in the management of patients with connective tissue disease. While some studies have shown a survival benefit with warfarin therapy in this disease, others have not. Accordingly, a state of clinical equipoise exists in relation to anticoagulation in SSc-PAH. With an over fivefold reduction in mortality demonstrated in some observational studies, the issue of anticoagulation in SSc-PAH demands resolution through a well-designed randomised controlled trial.
Keywords: scleroderma; systemic sclerosis; pulmonary arterial hypertension; anticoagulation; randomised controlled trial
Rights: © 2013 The Authors
RMID: 0020128936
DOI: 10.1111/imj.12111
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.